Business Context and Reporting Period
Trisalus Life Sciences, Inc. (TLSI) is a commercial-stage medical device and Phase I clinical-stage pharmaceutical company. The company markets the TriNav infusion system for liver and pancreatic cancer treatment and is developing nelitolimod, an immuno-oncology therapeutic. This Form 10-Q covers the quarterly period ended June 30, 2024.
Key Financial Metrics
| Metric | Three Months Ended June 30, 2024 | Six Months Ended June 30, 2024 | As of June 30, 2024 |
|---|---|---|---|
| Revenue | $7.4 million | $13.8 million | N/A |
| Gross Profit | $6.5 million | $11.9 million | N/A |
| Gross Margin | 87.6% | 86.4% | N/A |
| Net Loss (Common Stockholders) | $(5.1) million | $(19.2) million | N/A |
| Cash and Cash Equivalents | N/A | N/A | $16.5 million |
| Long-Term Debt (Net) | N/A | N/A | $21.3 million |
| Accumulated Deficit | N/A | N/A | $(265.9) million |
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 59.7% quarter-over-quarter and 82.0% year-over-year (six months), driven by increased sales of the TriNav device.
- Operating Expenses: Sales and marketing expenses increased significantly (71.9% QoQ) due to headcount expansion. Research and development expenses decreased 32.2% QoQ due to reduced clinical trial spending for nelitolimod.
- Non-Cash Gains/Losses: The company recorded a $13.7 million gain from the change in fair value of the contingent earnout liability, offset by a $9.0 million loss from changes in fair value of warrant and SEPA liabilities.
- Debt Financing: In April 2024, the company entered a credit agreement with OrbiMed, drawing an initial $25.0 million term loan, resulting in new interest expense.
Guidance, Outlook, and Risks
- Liquidity and Going Concern: Management has identified substantial doubt about the company's ability to continue as a going concern for the next 12 months. Existing cash and the initial OrbiMed draw are insufficient to fund projected requirements without additional financing.
- Financing Strategy: The company plans to fund operations through the end of 2025 by utilizing the remaining $25.0 million available under the OrbiMed Credit Agreement (subject to revenue milestones) and selling up to $30.0 million of common stock under the Standby Equity Purchase Agreement (SEPA) with Yorkville.
- Reimbursement: A new permanent HCPCS code for TriNav became effective January 1, 2024, replacing the expired transitional pass-through payment. There is no assurance that reimbursement rates will remain stable.
- Internal Controls: The company has identified material weaknesses in internal controls over financial reporting, specifically regarding the accounting for complex financial instruments (SEPA, warrants, debt) and the Business Combination. Remediation efforts are underway.
Investor Verification Checklist
- Cash Runway: Verify the company's ability to access the remaining $25 million from OrbiMed, which is contingent on achieving specific revenue targets ($30M and $50M trailing 12-month revenue).
- SEPA Utilization: Monitor the volume and pricing of shares sold under the SEPA, as this is a primary source of near-term liquidity.
- Reimbursement Stability: Confirm that the new HCPCS code (C9797) is being successfully utilized by hospitals and that reimbursement rates are not being challenged or reduced.
- Internal Control Remediation: Track progress on remediation of material weaknesses in financial reporting to ensure future filing reliability.
- Warrant Liability Volatility: Assess the impact of stock price fluctuations on the fair value of warrant and earnout liabilities, which significantly impact reported net income/loss.